Lung Cancers

New Targeted Therapies for Non-Small Cell Lung Cancer

The NCCN Guidelines® Non-Small Cell Lung Cancer are updated frequently throughout the year to include new approved agents and indications. It is difficult for clinicians to stay up-to-date on the most recent recommendations to improve outcomes for their patients with metastatic NSCLC. In addition, clinicians need to be aware of novel adverse reactions that may occur with the new targeted therapies.

NCCN Guidelines® Updates: Targeted Therapy for Patients with Metastatic Non-Small Cell Lung Cancer

This information was originally presented at the NCCN 23rd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care held in Orlando, Florida, from March 22 - 24, 2018.

Team-Based Case Review: Oligometastatic Prostate, Non-Small Cell Lung, and Colorectal Cancers

The role of metastasis-directed therapy (MDT) for patients with oligometastatic cancer is rapidly evolving, and trials have shown that integrating metastasis-directed therapy into the care of these patients can improve oncologic outcomes including time to disease progression and overall survival.

Advances in the Treatment of Non-Metastatic Non-Small Cell Lung Cancer

Clinicians should be aware of all the available systemic therapy regimens as well as updated guideline recommendations on biomarker testing and treatment to ensure that patients with non-metastatic NSCLC receive the most appropriate treatments.

Treatment Updates for Small Cell Lung Cancer

After decades of no change in treatment, practice changing therapies have now been added to the NCCN Guidelines for Small Cell Lung Cancer. This activity will help clinicians keep up to date with practice-changing strategies for SCLC.

Archived NCCN Tumor Boards: New Approaches to the Management of Resectable Non-Small Cell Lung Cancer

In recent years, several new systemic therapy regimens were approved by the FDA as additional neoadjuvant or adjuvant treatment options for eligible patients with resectable NSCLC and included in the NCCN Guidelines for NSCLC. Clinicians need to be aware of the updated treatment recommendations to ensure optimal outcomes for patients with early-stage NSCLC.

NCCN Tumor Boards: New Approaches to the Management of Resectable Non-Small Cell Lung Cancer

In recent years, several new systemic therapy regimens were approved by the FDA as additional neoadjuvant or adjuvant treatment options for eligible patients with resectable NSCLC and included in the NCCN Guidelines for NSCLC. Clinicians need to be aware of the updated treatment recommendations to ensure optimal outcomes for patients with early-stage NSCLC.

NCCN Guidelines® Insights - Lung Cancer Screening, Version 1.2025

These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Lung Cancer Screening.

Recorded Presentation from the NCCN Pharmacy Updates: Chemoimmunotherapy Updates in Advanced/Metastatic Non-Small Cell Lung Cancer

This webinar will provide a summary of the newest chemoimmunotherapy options in advanced NSCLC and the toxicities associated with these combination regimens.

NCCN Pharmacy Updates: Chemoimmunotherapy Updates in Advanced/Metastatic Non-Small Cell Lung Cancer